Life (Basel, Switzerland) · 2025
The ADVanced Organ Support (ADVOS) Hemodialysis System in Postoperative Cardiogenic Shock and Multiple Organ Failure: First Results in Cardiac Surgery Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Walter Veronika, Hinrichs Ekaterina, Alloush Tarek, de Garibay Aritz Perez Ruiz, Warnecke Gregor, Sommer Wiebke, Gravert Hanna, Grothusen Christina, Becker Janine, Thiem Alexander, Panholzer Bernd
Аннотация
BACKGROUND: The management of multiple organ failure in the vulnerable cohort of cardiac surgery patients with cardiogenic shock remains a significant challenge, often impairing patient survival. A multimodal approach at targeting organ dysfunction seems to be a promising strategy, encompassing both hemodynamic support as well as differentiated organ replacement therapy.
MATERIALS AND METHODS: In our retrospective study we examined the impact of the ADVOS (advanced organ support) system on overall outcomes and survival in an all-comers group of 22 cardiac surgery patients with postoperative cardiogenic shock and multiple organ failure.
AIMS: The objective of the study was to assess the feasibility and potential benefits of ADVOS treatment in this patient population.
RESULTS: The standard care management in combination with ADVOS therapy corrected acid-base balance (pH 7.33 vs. 7.44, p = 0.001; base excess -3.2 vs. 2.4 mmol/L, p < 0.001). This contributed to restoring hemodynamic balance after two consecutive ADVOS treatments (vasoactive inotropic score (VIS) 59 vs. 21, p = 0.007, noradrenaline 0.470 vs. 0.180 µg/kg/min, p = 0.009).
CONCLUSIONS: Our findings indicate that ADVOS treatment is both feasible and safe, with a substantial proportion of patients demonstrating improvements in organ function and overall outcomes.
MATERIALS AND METHODS: In our retrospective study we examined the impact of the ADVOS (advanced organ support) system on overall outcomes and survival in an all-comers group of 22 cardiac surgery patients with postoperative cardiogenic shock and multiple organ failure.
AIMS: The objective of the study was to assess the feasibility and potential benefits of ADVOS treatment in this patient population.
RESULTS: The standard care management in combination with ADVOS therapy corrected acid-base balance (pH 7.33 vs. 7.44, p = 0.001; base excess -3.2 vs. 2.4 mmol/L, p < 0.001). This contributed to restoring hemodynamic balance after two consecutive ADVOS treatments (vasoactive inotropic score (VIS) 59 vs. 21, p = 0.007, noradrenaline 0.470 vs. 0.180 µg/kg/min, p = 0.009).
CONCLUSIONS: Our findings indicate that ADVOS treatment is both feasible and safe, with a substantial proportion of patients demonstrating improvements in organ function and overall outcomes.